PHARMACIE DUCATEL - HERLAKIAN is a French company
founded 19 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in SAINT-ROMAIN-DE-COLBOSC (76430),
this company of category PME
shows in 2023 a revenue of 6.6 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE DUCATEL - HERLAKIAN (SIREN 491645958)
Indicator
2025
2024
2023
2022
2020
2019
2018
2017
Revenue
N/C
N/C
6 602 886 €
N/C
N/C
N/C
N/C
4 284 913 €
Net income
429 709 €
353 943 €
386 945 €
649 989 €
276 078 €
286 870 €
323 342 €
284 655 €
EBITDA
N/C
N/C
591 099 €
N/C
N/C
N/C
N/C
433 737 €
Net margin
N/C
N/C
5.9%
N/C
N/C
N/C
N/C
6.6%
Revenue and income statement
In 2025, PHARMACIE DUCATEL - HERLAKIAN generates positive net income of 430 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2025: 285 k€ -> 430 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
429 709 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 13%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 78%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
12.559%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
77.876%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2022
2023
2024
2025
Debt ratio
122.192
88.307
65.541
46.758
20.988
11.606
11.931
12.559
Financial autonomy
39.46
46.512
52.473
58.817
69.264
78.542
78.19
77.876
Repayment capacity
6.812
None
None
None
None
0.874
None
None
Cash flow / Revenue
6.481%
None%
None%
None%
None%
7.369%
None%
None%
Sector positioning
Debt ratio
12.562025
2023
2024
2025
Q1: 13.71
Med: 49.76
Q3: 129.07
Excellent
In 2025, the debt ratio of PHARMACIE DUCATEL - HERLA... (12.56) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
Financial autonomy
77.88%2025
2023
2024
2025
Q1: 33.42%
Med: 53.71%
Q3: 72.08%
Excellent
In 2025, the financial autonomy of PHARMACIE DUCATEL - HERLA... (77.9%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
Repayment capacity
0.87 years2023
2023
Q1: 0.95 years
Med: 3.58 years
Q3: 7.48 years
Excellent
In 2023, the repayment capacity of PHARMACIE DUCATEL - HERLA... (0.87) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 311.65. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2017
2018
2019
2020
2022
2023
2024
2025
Liquidity ratio
223.392
230.062
0.0
0.0
249.619
316.98
279.566
311.649
Interest coverage
5.929
None
None
None
None
2.131
None
None
Sector positioning
Liquidity ratio
311.652025
2023
2024
2025
Q1: 131.03
Med: 182.29
Q3: 258.7
Excellent
In 2025, the liquidity ratio of PHARMACIE DUCATEL - HERLA... (311.65) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
Interest coverage
2.13x2023
2023
Q1: 0.38x
Med: 2.71x
Q3: 6.47x
Average
In 2023, the interest coverage of PHARMACIE DUCATEL - HERLA... (2.1x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution PHARMACIE DUCATEL - HERLAKIAN
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2022
2023
2024
2025
Operating WCR
504 549 €
0 €
0 €
0 €
0 €
942 034 €
0 €
0 €
Inventory turnover (days)
0
0
0
0
0
44
0
0
Customer payment term (days)
3
0
0
0
0
3
0
0
Supplier payment term (days)
45
0
0
0
0
33
0
0
Positioning of PHARMACIE DUCATEL - HERLAKIAN in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of PHARMACIE DUCATEL - HERLAKIAN is estimated at
6 825 978 €
(range 4 632 141€ - 10 710 900€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
4632k€6825k€10710k€
6 825 978 €Range: 4 632 141€ - 10 710 900€
NAF 5 année 2025
Valuation method used
Net Income Multiple
429 709 €
×
15.9x
=6 825 979 €
Range: 4 632 141€ - 10 710 900€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE DUCATEL - HERLAKIAN with other companies in the same sector:
Frequently asked questions about PHARMACIE DUCATEL - HERLAKIAN
What is the revenue of PHARMACIE DUCATEL - HERLAKIAN ?
The revenue of PHARMACIE DUCATEL - HERLAKIAN in 2023 is 6.6 M€.
Is PHARMACIE DUCATEL - HERLAKIAN profitable?
Yes, PHARMACIE DUCATEL - HERLAKIAN generated a net profit of 430 k€ in 2025.
Where is the headquarters of PHARMACIE DUCATEL - HERLAKIAN ?
The headquarters of PHARMACIE DUCATEL - HERLAKIAN is located in SAINT-ROMAIN-DE-COLBOSC (76430), in the department Seine-Maritime.
Where to find the tax return of PHARMACIE DUCATEL - HERLAKIAN ?
The tax return of PHARMACIE DUCATEL - HERLAKIAN is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE DUCATEL - HERLAKIAN operate?
PHARMACIE DUCATEL - HERLAKIAN operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart